4-biphenyl-2'-allylacetic acid | 93319-28-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-biphenyl-2'-allylacetic acid
• 英文别名: 2-Biphenyl-4-yl-pent-4-ensaeure；2-biphenyl-4-yl-pent-4-enoic acid；2-(4-Phenylphenyl)pent-4-enoic acid
• CAS: 93319-28-9
• 化学式: C₁₇H₁₆O₂
• 分子量: 252.313
• InChiKey: QOJUQIFIZLZGIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-biphenyl-2'-allylacetic acid 在 氯化亚砜 作用下， 反应 2.0h， 生成
  参考文献：
  名称：

  通过直接钯催化酰胺的α-芳基化反应高度化学合成和对映选择性合成3-烯丙基-3-芳基吲哚

  摘要：

  据报道，一种新的NHC·Pd催化的酰胺的不对称α-芳基化反应可直接获得具有季碳中心的合成有价值的烯丙基化吲哚。通过引入新的手性NHC配体使反应成为可能。由其衍生的钯配合物将优异的反应性与对标题转化的高化学和对映选择性结合在一起。

  DOI：

  10.1021/ol1003093
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 、 溶剂黄146 作用下， 生成 4-biphenyl-2'-allylacetic acid
  参考文献：
  名称：

  Further Research on Biphenyl, Stilbene and Diphenylethane Derivatives—Potential Anticholesterinemic, Antirheumatic Drugs. VII

  摘要：

  DOI：

  10.1021/ja01570a057

文献信息

• The Ketene-Surrogate Coupling: Catalytic Conversion of Aryl Iodides into Aryl Ketenes through Ynol Ethers
  作者：Wenhan Zhang、Joseph M. Ready

  DOI：10.1002/anie.201405036

  日期：2014.8.18

  tert‐Butoxyacetylene is shown to undergo Sonogashira coupling with aryl iodides to yield aryl‐substituted tert‐butyl ynol ethers. These intermediates participate in a [1,5]‐hydride shift, which results in the extrusion of isobutylene and the generation of aryl ketenes. The ketenes are trapped in situ with multiple nucleophiles or undergo electrocyclic ring closure to yield hydroxynaphthalenes and quinolines

  表明叔丁氧基乙炔与芳基碘化物发生 Sonogashira 偶联，生成芳基取代的叔丁基炔醇醚。这些中间体参与[1,5]-氢化物转移，导致异丁烯的挤出和芳基烯酮的生成。烯酮被多个亲核试剂原位捕获或进行电环闭合以产生羟基萘和喹啉。
• NK1 and NK3 antagonists
  申请人：O'Neill T. Brian

  公开号：US20050256164A1

  公开（公告）日：2005-11-17

  The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions.

  这项发明涉及一种具有神经激肽抑制性能的化合物，包括该化合物的药物组合物以及用于神经激肽介导疾病的治疗方法。
• Cu-catalyzed enantioselective decarboxylative cyanation <i>via</i> the synergistic merger of photocatalysis and electrochemistry
  作者：Yin Yuan、Junfeng Yang、Junliang Zhang

  DOI：10.1039/d2sc05428k

  日期：——

  The development of an efficient and straightforward method for decarboxylative coupling using common alkyl carboxylic acid is of great value. However, decarboxylative coupling with nucleophiles always needs stoichiometric chemical oxidants or substrate prefunctionalization. Herein, we report a protocol for Cu-catalyzed enantioselective decarboxylative cyanation via the merger of photocatalysis and

  开发一种使用普通烷基羧酸进行脱羧偶联的有效且简单的方法具有重要价值。然而，与亲核试剂的脱羧偶联总是需要化学计量的化学氧化剂或底物预功能化。在此，我们报告了通过光催化和电化学相结合的铜催化对映选择性脱羧氰化的方案。 CeCl 3和Cu/BOX作为助催化剂促进脱羧和氰化，两种催化剂均通过阳极氧化再生。该方法通过光电催化建立了对映选择性转化的概念验证。 DFT 计算研究提供了对映选择性控制的机制见解。
• PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS
  申请人：Pfizer Products Inc.

  公开号：EP1748984A1

  公开（公告）日：2007-02-07
• [EN] PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS<br/>[FR] DERIVES DE PIPERIDINE EN TANT QU'ANTAGONISTES DE NK1 ET NK3
  申请人：PFIZER PROD INC

  公开号：WO2005110987A1

  公开（公告）日：2005-11-24

  The invention relates to compounds according to formula I exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising, same and a method of treatment for neurokinin-mediated conditions. Formula (I) or a pharmaceutically acceptable salt or solvate thereof wherein: m,=0 or 1; n =0 or 1; s=0 or 1; L is -O- or -N(R4 )-; R1 and R2 are each independently H, aryl, heteroaryl, -(C1-C6)atkylheterocyloalkyl, -(C1-C6)alkylheterocycloalkyl, -(C1-C6)alkylheteroaryl, -(C1-C6)alkyl-O-aryl, -(C1- C6)alkylaryl, and -CH2 N(R4)(R5), wherein each of said heterocyloalkyl, -(C1-C6)alkylheterocycloalkyl, -(C1-C6)alkylheteroaryl, -(C1-C6)alkyl-0-aryl, aryl, -(C1-C6)alkylaryl, heteroaryl, and -CH2N(R4)(R5), is optionally substituted with 1-3 moieties independently selected from X', Y' or Z'; R3 is H, CF3, OH, or-(C1-C6)alkyl; R4, and R5, are each independently selected from H, -(C1-C6)alkyl, or -(C1-C6)(C=0)R7; R7 is (C1-C6)alkyl, OH, -N(R4)(R), or -OR4; R8 and R9 are each independently (C1-C6)alkyl; X, Y, X', Y' and Z' are each independently selected from H, -(C1-C6)alkyl, -(C1-C6)alkyl-NR 4R5, CF3, OH, -O-(C1-C6)alkyl, -(C1-C6)alkyl-C(=0)R7, aryl, heteroaryl, cycloalkyl, -N02, -(C1-C6)alkylaryl, -0-aryl, halogen, CN, -CH3N(R4)(R5), -C(=O)R7, -C(=O)R7, -R6C(=0)R7 or -R6C(=O)NR4R5; and R6 is a bond, -CH2-, -0-, or -NR4­.